<!DOCTYPE html>
<html lang="en"><head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1"><!-- Begin Jekyll SEO tag v2.8.0 -->
<title>Active Learning Free Energy Calculations | Karl Leswing</title>
<meta name="generator" content="Jekyll v4.4.1" />
<meta property="og:title" content="Active Learning Free Energy Calculations" />
<meta property="og:locale" content="en_US" />
<meta name="description" content="official link" />
<meta property="og:description" content="official link" />
<link rel="canonical" href="http://karlleswing.com/2019/09/06/FEPActiveLearningAgain.html" />
<meta property="og:url" content="http://karlleswing.com/2019/09/06/FEPActiveLearningAgain.html" />
<meta property="og:site_name" content="Karl Leswing" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2019-09-06T00:00:00+00:00" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="Active Learning Free Energy Calculations" />
<script type="application/ld+json">
{"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2019-09-06T00:00:00+00:00","datePublished":"2019-09-06T00:00:00+00:00","description":"official link","headline":"Active Learning Free Energy Calculations","mainEntityOfPage":{"@type":"WebPage","@id":"http://karlleswing.com/2019/09/06/FEPActiveLearningAgain.html"},"url":"http://karlleswing.com/2019/09/06/FEPActiveLearningAgain.html"}</script>
<!-- End Jekyll SEO tag -->
<link rel="stylesheet" href="/assets/main.css"><link type="application/atom+xml" rel="alternate" href="http://karlleswing.com/feed.xml" title="Karl Leswing" /></head>
<body><header class="site-header" role="banner">

  <div class="wrapper"><a class="site-title" rel="author" href="/">Karl Leswing</a><nav class="site-nav">
        <input type="checkbox" id="nav-trigger" class="nav-trigger" />
        <label for="nav-trigger">
          <span class="menu-icon">
            <svg viewBox="0 0 18 15" width="18px" height="15px">
              <path d="M18,1.484c0,0.82-0.665,1.484-1.484,1.484H1.484C0.665,2.969,0,2.304,0,1.484l0,0C0,0.665,0.665,0,1.484,0 h15.032C17.335,0,18,0.665,18,1.484L18,1.484z M18,7.516C18,8.335,17.335,9,16.516,9H1.484C0.665,9,0,8.335,0,7.516l0,0 c0-0.82,0.665-1.484,1.484-1.484h15.032C17.335,6.031,18,6.696,18,7.516L18,7.516z M18,13.516C18,14.335,17.335,15,16.516,15H1.484 C0.665,15,0,14.335,0,13.516l0,0c0-0.82,0.665-1.483,1.484-1.483h15.032C17.335,12.031,18,12.695,18,13.516L18,13.516z"/>
            </svg>
          </span>
        </label>

        <div class="trigger"><a class="page-link" href="/posts/">Posts</a></div>
      </nav></div>
</header>
<main class="page-content" aria-label="Content">
      <div class="wrapper">
        <script type="text/javascript" async
  src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML">
</script>
<article class="post">

  <!--<header class="post-header">
    <h1 class="post-title">Active Learning Free Energy Calculations</h1>
  </header>-->

  <div class="post-content">
    <p><img src="/assets/2019_03_15/preview.jpg" alt="overview_pic" />
<a href="https://pubs.acs.org/doi/abs/10.1021/acs.jcim.9b00367">official link</a></p>

<h3 id="abstract">Abstract</h3>
<p>The hit-to-lead and lead optimization processes usually involve the design, synthesis, and profiling of thousands of analogs prior to clinical candidate nomination. A hit finding campaign may begin with a virtual screen that explores millions of compounds, if not more. However, this scale of computational profiling is not frequently performed in the hit-to-lead or lead optimization phases of drug discovery. This is likely due to the lack of appropriate computational tools to generate synthetically tractable lead-like compounds in silico, and a lack of computational methods to accurately profile compounds prospectively on a large scale. Recent advances in computational power and methods provide the ability to profile much larger libraries of ligands than previously possible. Herein, we report a new computational technique, referred to as “PathFinder”, that uses retrosynthetic analysis followed by combinatorial synthesis to generate novel compounds in synthetically accessible chemical space. In this work, the integration of PathFinder-driven compound generation, cloud-based FEP simulations, and active learning are used to rapidly optimize R-groups, and generate new cores for inhibitors of cyclin-dependent kinase 2 (CDK2). Using this approach, we explored &gt;300 000 ideas, performed &gt;5000 FEP simulations, and identified &gt;100 ligands with a predicted IC50 &lt; 100 nM, including four unique cores. To our knowledge, this is the largest set of FEP calculations disclosed in the literature to date. The rapid turnaround time, and scale of chemical exploration, suggests that this is a useful approach to accelerate the discovery of novel chemical matter in drug discovery campaigns.</p>

  </div>

</article>

      </div>
    </main><footer class="site-footer">

  <div class="wrapper">

    <h2 class="footer-heading">Karl Leswing</h2>

    <div class="footer-col-wrapper">
      <div class="footer-col footer-col-1">
        <ul class="contact-list">
          <li>
            
              Karl Leswing
            
            </li>
            
            <li><a href="mailto:lilleswing@gmail.com">lilleswing@gmail.com</a></li>
            
        </ul>
      </div>

      <div class="footer-col footer-col-2">
        <ul class="social-media-list">
          
          <li>
            <a href="https://github.com/lilleswing"><span class="icon icon--github"><svg viewBox="0 0 16 16" width="16px" height="16px"><path fill="#828282" d="M7.999,0.431c-4.285,0-7.76,3.474-7.76,7.761 c0,3.428,2.223,6.337,5.307,7.363c0.388,0.071,0.53-0.168,0.53-0.374c0-0.184-0.007-0.672-0.01-1.32 c-2.159,0.469-2.614-1.04-2.614-1.04c-0.353-0.896-0.862-1.135-0.862-1.135c-0.705-0.481,0.053-0.472,0.053-0.472 c0.779,0.055,1.189,0.8,1.189,0.8c0.692,1.186,1.816,0.843,2.258,0.645c0.071-0.502,0.271-0.843,0.493-1.037 C4.86,11.425,3.049,10.76,3.049,7.786c0-0.847,0.302-1.54,0.799-2.082C3.768,5.507,3.501,4.718,3.924,3.65 c0,0,0.652-0.209,2.134,0.796C6.677,4.273,7.34,4.187,8,4.184c0.659,0.003,1.323,0.089,1.943,0.261 c1.482-1.004,2.132-0.796,2.132-0.796c0.423,1.068,0.157,1.857,0.077,2.054c0.497,0.542,0.798,1.235,0.798,2.082 c0,2.981-1.814,3.637-3.543,3.829c0.279,0.24,0.527,0.713,0.527,1.437c0,1.037-0.01,1.874-0.01,2.129 c0,0.208,0.14,0.449,0.534,0.373c3.081-1.028,5.302-3.935,5.302-7.362C15.76,3.906,12.285,0.431,7.999,0.431z"/></svg>
</span><span class="username">lilleswing</span></a>

          </li>
          

          
          <li>
            <a href="https://twitter.com/karl_leswing"><span class="icon icon--twitter"><svg viewBox="0 0 16 16" width="16px" height="16px"><path fill="#828282" d="M15.969,3.058c-0.586,0.26-1.217,0.436-1.878,0.515c0.675-0.405,1.194-1.045,1.438-1.809c-0.632,0.375-1.332,0.647-2.076,0.793c-0.596-0.636-1.446-1.033-2.387-1.033c-1.806,0-3.27,1.464-3.27,3.27 c0,0.256,0.029,0.506,0.085,0.745C5.163,5.404,2.753,4.102,1.14,2.124C0.859,2.607,0.698,3.168,0.698,3.767 c0,1.134,0.577,2.135,1.455,2.722C1.616,6.472,1.112,6.325,0.671,6.08c0,0.014,0,0.027,0,0.041c0,1.584,1.127,2.906,2.623,3.206 C3.02,9.402,2.731,9.442,2.433,9.442c-0.211,0-0.416-0.021-0.615-0.059c0.416,1.299,1.624,2.245,3.055,2.271 c-1.119,0.877-2.529,1.4-4.061,1.4c-0.264,0-0.524-0.015-0.78-0.046c1.447,0.928,3.166,1.469,5.013,1.469 c6.015,0,9.304-4.983,9.304-9.304c0-0.142-0.003-0.283-0.009-0.423C14.976,4.29,15.531,3.714,15.969,3.058z"/></svg>
</span><span class="username">karl_leswing</span></a>

          </li>
          
        </ul>
      </div>

      <div class="footer-col footer-col-3">
            <img src=https://imgs.xkcd.com/comics/here_to_help.png title="&quot;We TOLD you it was hard.&quot; &quot;Yeah, but now that I&#39;VE tried, we KNOW it&#39;s hard.&quot;" alt="Here to Help" srcset="//imgs.xkcd.com/comics/here_to_help_2x.png 2x"/>
      </div>
    </div>

  </div>

</footer>
</body>

</html>
